Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Giagounidis, Aristoteles, Fenaux, Pierre, Mufti, Ghulam J., Muus, Petra, Platzbecker, Uwe, Sanz, Guillermo, Cripe, Larry, Von Lilienfeld-Toal, Marie, Wells, Richard A.
Format: Artigo
Jezik:Inglês
Izdano: Springer-Verlag 2008
Teme:
Review Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2275303/
https://ncbi.nlm.nih.gov/pubmed/18265982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-008-0449-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items